Recombinant Granulin Therapy for Lysosomal Defect Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for frontotemporal dementia and Alzheimer's disease associated with lysosomal defects lack effective solutions, as existing therapies fail to adequately address the underlying lysosomal dysfunction and neurodegeneration caused by granulin mutations.
Innovation Solution
Development of purified and recombinant granulins, including variants and fusion proteins, which are administered to treat or prevent diseases by targeting lysosomal defects, with methods involving intravenous, intracerebroventricular, or direct brain infusion to restore normal granulin levels and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for frontotemporal dementia and Alzheimer's disease, then treatment is provided, but the underlying lysosomal dysfunction and neurodegeneration caused by granulin mutations are not adequately addressed
Solution Approach 1:
The patent uses recombinant granulins as intermediary substances to mediate between the administered therapy and the lysosomal dysfunction. These granulins act as mediators that specifically target and correct the lysosomal defects caused by granulin mutations, bridging the gap between existing therapies and the underlying pathological mechanism.
Solution Approach 2:
The patent converts the harmful effect of granulin mutations (lysosomal dysfunction) into a beneficial therapeutic target. By administering recombinant granulins, the therapy exploits the specific mechanism of lysosomal dysfunction to deliver targeted treatment, turning the pathological pathway into a therapeutic opportunity.
2Reliability
If purified and recombinant granulins are administered to restore normal granulin levels, then lysosomal dysfunction is rescued, but complex administration methods (intravenous, intracerebroventricular, or direct brain infusion) are required
Solution Approach 1:
The patent segments the administration approach into multiple routes (intravenous, intracerebroventricular, direct brain infusion) to address different severity levels and patient needs. This segmentation allows selection of the least complex method that achieves the desired therapeutic effect.
Solution Approach 2:
The recombinant granulin compositions are designed with universal applicability across multiple administration routes and disease stages. The same core composition can be delivered through different pathways, making the therapy adaptable to various clinical scenarios without requiring entirely different formulations.
Data Source
AI summary
This disclosure relates to purified and recombinant granulins, fusions, or variants and vectors encoding the same. In certain embodiments, this disclosure relates to uses of these granulins or vectors, alone or in combination, in the treatment or prevention of diseases or conditions associated with lysosomal defects such as frontotemporal dementia and Alzheimer's disease.